| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $20.3M | +68.4% | +1086.2% |
| SG&A Expense | $5.5M | -38.1% | +38.2% |
| Operating Income | -$25.9M | -23.1% | -130.4% |
| Income Tax | $0 | — | — |
| Net Income | -$24.6M | -12.9% | -150.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $133.3M | -12.7% | +826.0% |
| Current Assets | $134.6M | -12.8% | +760.1% |
| Total Assets | $138.3M | -12.2% | +780.8% |
| Current Liabilities | $20.3M | +21.2% | +369.8% |
| Total Liabilities | $21.6M | +19.0% | +400.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$44.8M | — | — |
| Capital Expenditures | $726K | — | — |
| Investing Cash Flow | -$726K | — | — |
| Financing Cash Flow | $144.1M | — | — |
| Free Cash Flow | -$45.5M | — | — |
| $116.6M |
| -16.2% |
| +925.3% |